← Back

Baotou Dongbao Bio-Tech Co Ltd

Baotou Dongbao Bio-Tech Co., Ltd. designs, researches, develops, produces, and sells gelatin and collagen in China and internationally. Its products include pharmaceutical, food additive, and photographic gelatin; hydrolyzed collagen, collagen peptide, fish collagen peptide, and agglomerated collagen; and private label collagen and unflavored collagen jars. The company also offers organic, water-soluble, and compound microbial fertilizers; industrial and feed grade calcium hydrogen phosphate; and empty capsules. Founded in 1960, it is based in Baotou, China.

Price · split & dividend adjusted
News & notes moving 300239.CS
300239.CS

Dongbao Biotech Releases 2026 Interim Report with Net Profit of 37.404 Million Yuan

Dongbao Biotech released its 2026 interim report on August 24, 2026. The company's total operating revenue was 415 million yuan, net profit attributable to the parent company was 37.404 million yuan, and net cash inflow from operating activities was 54.5212 million yuan. The company's latest asset-liability ratio was 33.23 percent, up 0.94 percentage points from the previous quarter. Its latest gross margin was 22.08 percent, down 2.21 percentage points from the previous quarter and down 3.36 percentage points from the same period last year. Its latest return on equity was 2.13 percent, down 0.03 percentage points from the same period last year. Diluted earnings per share were 0.06 yuan. The latest total asset turnover was 0.16 times, and the latest inventory turnover was 0.81 times. The company had 20,200 shareholders, and the top ten shareholders held 210 million shares, accounting for 35.35 percent of total share capital.
300239.CS
Jiemian·26dRead more →
300239.CS▲2

Dongbao Bio's first-half 2026 net profit was 37.404 million yuan, up 1.18% year on year

Dongbao Bio disclosed its 2026 semi-annual report. In the first half, total operating revenue reached 415 million yuan, up 12.37% year on year. Net profit attributable to the parent company was 37.404 million yuan, up 1.18% year on year. Net profit after deducting non-recurring items was 33.6014 million yuan, up 0.50% year on year. Net cash flow from operating activities was 54.5212 million yuan, up 8.41% year on year. Basic earnings per share were 0.063 yuan, and the weighted average return on equity was 2.15%. Based on the closing price on August 21, the company's price-to-earnings ratio on a trailing twelve-month basis was about 57.11 times, its price-to-book ratio on a latest-filing basis was about 1.78 times, and its price-to-sales ratio on a trailing twelve-month basis was about 3.96 times. The company is mainly engaged in the research, development, production and sales of gelatin, collagen, hollow capsules and related derivative products.
300239.CS ▲
中国证券报·27dRead more →
300239.CS

Dongbao Bio first-half net profit attributable to parent 37.4 million yuan, up 1.2% year on year

Dongbao Bio released its 2026 half-year report. Net profit attributable to the parent in the first half was 37.4 million yuan, up 1.2% year on year. Operating revenue was 415 million yuan, up 12.4% year on year. Net profit attributable to the parent excluding non-recurring items was 33.6 million yuan, up 0.5% year on year. Net operating cash flow was 54.52 million yuan, up 8.4% year on year. Second-quarter operating revenue was 224 million yuan, up 23.8% year on year, while net profit attributable to the parent was 17.71 million yuan, down 1.2% year on year. Leveraging its collagen extraction strengths, the company is implementing a collagen plus strategy covering products such as gelatin, collagen, and empty capsules, and said it has consolidated its competitive edge in niche markets including pharmacopoeia grade-two gelatin and empty capsules.
300239.CS
财中社·27dRead more →
© 2026 MarketDXAsset